,2024-02-282024-02-282008Kurt, M. vd. (2008)."Comparison of protracted infusion 5-fluorouracil and capecitabine in adjuvant chemoradiotherapy for rectal cancer". Hepato-Gastroenterology, 55(85), 1158-1163.0172-6390https://hdl.handle.net/11452/40030Background/Aims: 5-Fluorouracil-based chemoradiotherapy is the most widely used treatment modality in the adjuvant treatment of rectal cancer. Capecitabine represents a valuable alternative to 5-Fluorouracil in this situation. Methodology: Patients with stage II and stage III rectal adenocarcinoma, who were included in this analysis, received adjuvant chemoradiotherapy consisting of external-beam radiotherapy (50.4-54Gy) either with 5-Fluorouracil at a median dose of 300mg/m(2)/day by protracted venous infusion for 5 days a week, or capecitabine at a median dose of 1650mg/m(2)/day for 5 days a week after surgery. The data concerning the toxicity and the efficacy of the treatments were compared in patients treated with 5-Fluorouracil- and capecitabine-based chemoradiotherapy. Results: Forty-three patients received 5-Fluorouracil, and 24 patients received capecitabine during adjuvant radiotherapy. Although there were no differences between the groups in terms of toxicity rates, distant metastasis-free survival, disease-free survival, and overall survival rates; a trend for improved loco-regional recurrence-free survival rate was observed in the capecitabine arm (p=0.063). Conclusions: Capecitabine is at least as effective as 5-Fluorouracil in the postoperative treatment of rectal adenocarcinoma. Considering the trend for improved loco-regional recurrence-free survival rate in the capecitabine arm, it seems that the drug exerts better synergy with radiotherapy in this situation.eninfo:eu-repo/semantics/closedAccessCapecitabineChemoradiotherapyRectal cancerFluorouracil plus leucovorinMetastatic colorectal-cancerOral capecitabinePreoperativeChemoradiationConcurrent radiotherapyRadiation-therapyPhase-iCombinationChemotherapyPatternsGastroenterology & hepatologySurgeryAdenocarcinomaAdultAgedAged, 80 and overAntimetabolites, antineoplasticChemotherapyAdjuvantCohort studiesDeoxycytidineDisease-free survivalFemaleFluorouracilHumansInfusions, intravenousMaleMiddle agedRadiotherapy, adjuvantRectal neoplasmsRetrospective studiesTreatment outcomeYoung adultArticle0002589948000022-s2.0-5814937445911581163558518795649Gastroenterology & hepatologySurgeryRectum Tumor; Chemoradiotherapy; Neoadjuvant TherapyAntineoplastic antimetaboliteAdjuvant chemotherapyAdjuvant therapyAdultAgedArticleCohort analysisComparative studyDisease free survivalFemaleHumanIntravenous drug administrationMaleMiddle agedMortalityPathologyRectum tumorRetrospective studyTreatment outcome